drugset / Trial / NCT06577376
A PhaseⅠ/Ⅱ Study of Simmitinib or Irinotecan Liposomes Combined With DP303c in Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This study is divided into two parts: Cohort 1 and Cohort 2. Cohort 1 includes the dose escalation phase of DP303c combined with simmitinib, as well as the randomized controlled trial (RCT) phase of DP303c combined with simmitinib; Cohort 2 includes dose escalation/dose extension of DP303c combined with irinotecan liposomes, as well as RCT stage of DP303c combined with irinotecan liposomes.
Timeline
- Start
- 2024-08-26
- Primary completion
- 2026-08-26
- Completion
- 2027-08-26
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Docetaxel | Small molecule | — | — |
| Comparator | Irinotecan | Small molecule | — | — |
| Subject | Irinotecan liposomes | Unknown | — | — |
| Comparator | Paclitaxel | Small molecule | — | — |
| Subject | Simmitinib | Small molecule | — | Oral |
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | — | Intravenous |